These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 17827637)
1. Deferasirox: the new oral iron chelator. Dubey AP; Sudha S; Parakh A Indian Pediatr; 2007 Aug; 44(8):603-7. PubMed ID: 17827637 [TBL] [Abstract][Full Text] [Related]
2. Exjade (ICL 670): A new oral iron chelator. Agarwal MB J Assoc Physicians India; 2006 Mar; 54():214-7. PubMed ID: 16800349 [TBL] [Abstract][Full Text] [Related]
3. Deferasirox--an oral agent for chronic iron overload. Vanorden HE; Hagemann TM Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647 [TBL] [Abstract][Full Text] [Related]
4. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Fischer R; Piga A; Harmatz P; Nielsen P Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683 [TBL] [Abstract][Full Text] [Related]
5. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. Taher AT; Temraz S; Cappellini MD Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402 [TBL] [Abstract][Full Text] [Related]
6. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. Jetsrisuparb A; Komvilaisak P; Wiangnon S; Jetsrisuparb C J Pediatr Hematol Oncol; 2010 Jul; 32(5):400-3. PubMed ID: 20505533 [TBL] [Abstract][Full Text] [Related]
7. Recent developments in iron chelation therapy. Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910 [TBL] [Abstract][Full Text] [Related]
8. Deferasirox (Exjade) for the treatment of iron overload. Cappellini MD; Taher A Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154 [TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in Thai thalassemic children treated with iron chelation. Torcharus K; Pankaew T Southeast Asian J Trop Med Public Health; 2011 Jul; 42(4):951-9. PubMed ID: 22299478 [TBL] [Abstract][Full Text] [Related]
10. Objectives and mechanism of iron chelation therapy. Hershko C; Link G; Konijn AM; Cabantchik ZI Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658 [TBL] [Abstract][Full Text] [Related]
11. Deferasirox for transfusion-related iron overload: a clinical review. Lindsey WT; Olin BR Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472 [TBL] [Abstract][Full Text] [Related]
13. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Kontoghiorghes GJ Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978 [TBL] [Abstract][Full Text] [Related]
14. Oral chelation: should it be used with young children? Mednick LM; Braunstein J; Neufeld E Pediatr Blood Cancer; 2010 Oct; 55(4):603-5. PubMed ID: 20806359 [TBL] [Abstract][Full Text] [Related]
15. Deferasirox. Stumpf JL Am J Health Syst Pharm; 2007 Mar; 64(6):606-16. PubMed ID: 17353569 [TBL] [Abstract][Full Text] [Related]
16. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620 [TBL] [Abstract][Full Text] [Related]
17. Deferasirox in thalassemia patients with end-stage renal disease. Beydoun HG; Saliba AN; Taher AT Am J Hematol; 2016 Oct; 91(10):E456-7. PubMed ID: 27342388 [No Abstract] [Full Text] [Related]
18. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173 [TBL] [Abstract][Full Text] [Related]
19. Deferasirox: pharmacokinetics and clinical experience. Galanello R; Campus S; Origa R Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640 [TBL] [Abstract][Full Text] [Related]
20. Iron mobilization using chelation and phlebotomy. Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]